The effects AZD8529 on cognition and negative symptoms in schizophrenics
Study identifier:D2285M00016
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Single Center, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Study to Access an Early Signal of Efficacy for Cognition and Negative Symptoms with AZD8529 in Patients with Schizophrenia
Medical condition
schizophrenia
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD8529, Placebo to match AZD8529
Sex
All
Actual Enrollment
59
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Nov 2009
Primary Completion Date: 01 Oct 2011
Study Completion Date: 01 Oct 2011
Study design
Allocation: Randomized
Endpoint Classification: N/A
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Oct 2011 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 80 mg AZD8529 | Drug: AZD8529 2 capsules by mouth for 3 days |
| Placebo Comparator: 2 Placebo | Drug: Placebo to match AZD8529 2 capsules by mouth for 3 days |
Contacts
Investigators
Principal Investigator
Raquel Gur
Hospital of the University of Pennsylvania, Dept of Psychiatry, Neuropsychiatry Section
